Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BCMA Dual Nanobody CAR-T Cells for DSA-Positive Transplantation Candidates
NCT07451236Phase 2Not yet recruiting
- Sponsor
- Yingjun Biotech
- Start
- Mar 2026
- Primary completion
- Jun 2027
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Yingjun Biotech. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 1 month, Incidence and severity of Immune Effector Cell-Associated Neurotoxicity Syndrome at 1 month and 1 more. Planned start Mar 2026; status: not yet recruiting.
Beyond the preview
Go deeper on NCT07451236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451236.